pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer
Phase 1 · other · Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer for Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer is a Phase 1 program (other) at Amgen with 1 ClinicalTrials.gov record(s).
Internal code 20200040
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amgen
- Phase
- Phase 1
- Modality
- other
- Indication
- Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
- Status
- active
- Trials
- 1